Segui
Morteza Azhdarzadeh
Morteza Azhdarzadeh
Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tabriz
Email verificata su alumnus.tums.ac.ir
Titolo
Citata da
Citata da
Anno
Development of azithromycin–PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi
G Mohammadi, H Valizadeh, M Barzegar-Jalali, F Lotfipour, K Adibkia, ...
Colloids and Surfaces B: Biointerfaces 80 (1), 34-39, 2010
1752010
Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer
M Azhdarzadeh, F Atyabi, AA Saei, BS Varnamkhasti, Y Omidi, M Fateh, ...
Colloids and Surfaces B: Biointerfaces 143, 224-232, 2016
1542016
Nanotoxicology: advances and pitfalls in research methodology
M Azhdarzadeh, AA Saei, S Sharifi, MJ Hajipour, AM Alkilany, ...
Nanomedicine 10 (18), 2931-2952, 2015
932015
Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core–shell nanoparticles
BS Varnamkhasti, H Hosseinzadeh, M Azhdarzadeh, SY Vafaei, ...
International journal of pharmaceutics 494 (1), 430-444, 2015
922015
MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery
E Sayari, M Dinarvand, M Amini, M Azhdarzadeh, E Mollarazi, Z Ghasemi, ...
International journal of pharmaceutics 473 (1-2), 304-315, 2014
922014
Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies
F Talaei, F Atyabi, M Azhdarzadeh, R Dinarvand, A Saadatzadeh
European Journal of Pharmaceutical Sciences 49 (4), 712-722, 2013
862013
Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria
M Azhdarzadeh, F Lotfipour, P Zakeri-Milani, G Mohammadi, H Valizadeh
Advanced Pharmaceutical Bulletin 2, 2012
702012
Antibacterial activity of clarithromycin loaded PLGA nanoparticles
H Valizadeh, G Mohammadi, R Ehyaei, M Milani, M Azhdarzadeh, ...
Die Pharmazie-An International Journal of Pharmaceutical Sciences 67 (1), 63-68, 2012
512012
Sensing of Alzheimer’s disease and multiple sclerosis using nano-bio interfaces
MJ Hajipour, F Ghasemi, H Aghaverdi, M Raoufi, U Linne, F Atyabi, ...
Journal of Alzheimer's Disease 59 (4), 1187-1202, 2017
422017
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling …
P Hassanzadeh, F Atyabi, R Dinarvand, AR Dehpour, M Azhdarzadeh, ...
DARU Journal of Pharmaceutical Sciences 25 (1), 1-16, 2017
402017
Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-Label Single-Arm Clinical Trial
P Payandemehr, M Azhdarzadeh, H Bahrami-Motlagh, A Hadadi, ...
Advanced Journal of Emergency Medicine 4 (2s), e51-e51, 2020
232020
External magnetic fields affect the biological impacts of superparamagnetic iron nanoparticles
S Shanehsazzadeh, A Lahooti, MJ Hajipour, M Ghavami, M Azhdarzadeh
Colloids and Surfaces B: Biointerfaces 136, 1107-1112, 2015
232015
Serum multivalent cationic pattern: speculation on the efficient approach for detection of Alzheimer's disease
M Azhdarzadeh, M Noroozian, H Aghaverdi, SM Akbari, L Baum, ...
Scientific reports 3 (1), 1-6, 2013
222013
Is amyloid-β an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-β function the real mechanism?
A ManafiRad, F Farzadfar, L Habibi, M Azhdarzadeh, H Aghaverdi, ...
Journal of Alzheimer's Disease 42 (1), 69-85, 2014
172014
Core shell methyl methacrylate chitosan nanoparticles: In vitro mucoadhesion and complement activation
F TALAEI, M AZHDARZADEH, NH HASHEMI, M MOOSAVI, ...
Daru, 2011
152011
A Randomized, Double-blind, Parallel Pharmacokinetic Study Comparing the Trastuzumab Biosimilar Candidate, AryoTrust®, and Reference Trastuzumab in Healthy Subjects
M Farmahani Farahani, P Maghzi, N Jafari Aryan, B Payandemehr, ...
Expert Opinion on Investigational Drugs, 2020
62020
Amyloid fibril inhibition, acceleration, or fragmentation; Are nano-based approaches advance in the right direction?
MJ Hajipour, H Mohammad-Beigi, I Nabipour, N Mahmoudi, ...
Nano Today 35, 100983, 2020
52020
A randomized pharmacokinetic-pharmacodynamic evaluation of the potential biosimilar interferon beta-1a product, CinnoVex®
M Scheinin, Z Lovró, IH Maadik, J Suopanki-Lalowski, SH Seyedagha, ...
Expert Opinion on Biological Therapy, 1-10, 2021
12021
Study of anti-microbial effects of Clarithromycin nanosuspensions against Staphylococcus aureus and Salmonella typhi
F Lotfipour, H Valizadeh, M Azhdarzadeh, P Zakeri Milani
Pharmaceutical Sciences 18 (1), 1-8, 2012
12012
STUDY OF ANTI-MICROBIAL EFFECTS OF AZITHROMYCIN NANOSUSPENSIONS IN COMPARISON WITH DRUG SOLUTION
M AZHDARZADEH, H VALIZADEH, F LOTFIPOUR, G MOHAMMADI, ...
1*
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20